In contrast, Triptolide not only inhibits osteoclast activity but also modulates upstream tumor-derived factors, such as parathyroid hormone-related protein (PTHrP)-induced RANKL expression, thereby offering a more comprehensive approach to controlling tumor-induced bone destruction. The gene discussed is PTHLH; the disease is neoplasm.